Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature

Guerra, Nadia; Matas‐García, Ana; Serra‐García, Laura; Morgado‐Carrasco, Daniel; Padrosa, Joan; Aldecoa, Ibán; Duque, Yaiza; Casal-Domínguez, María; Muñoz-Braceras, Sandra; Aránega, Raquel; Moreno-Lozano, Pedro; Cantó-Santos, Judith; Garrabou, Glòria; Ruiz-Ortiz, Estíbaliz; Trallero-Araguás, Ernesto; Selva-O’Callaghan, Albert; Grau, Josep M.; Puig, Susana; Torres-Ruíz, Jiram; Mammen, Andrew L.; Fernández, Iago Pinal; Milisenda, José César

doi:10.1016/j.autrev.2023.103375

Cited by 7 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PD-1/PD-LI axis induces T-cell tolerance by inhibiting TRC signaling ( 163 ). They can also inhibit the proliferation of CD8+ T lymphocytes to promote the death of antigen-specific T cells and tumor-infiltrating T lymphocytes, thereby suppressing the antitumor immune response ( 164 ). In addition, the PD-1/PD-LI axis can inhibit the PI3K/ALK and RAS/MEK/ERK signaling pathways to hinder the normal proliferation cycle of T lymphocytes, and the PD-1/PD-LI axis can downregulate the phosphorylation of mTOR, AKT, and ERK2 to upregulate the expression of PTEN, which promotes the transformation of CD4+ T cells into Tregs and inhibits the activity of effector T cells ( 165 ).…”

Section: The Potential Of Antitumor Therapy On the Immune Microenviro...mentioning

confidence: 99%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The occurrence of ovarian cancer (OC) is a major factor in women’s mortality rates. Despite progress in medical treatments, like new drugs targeting homologous recombination deficiency, survival rates for OC patients are still not ideal. The tumor microenvironment (TME) includes cancer cells, fibroblasts linked to cancer (CAFs), immune-inflammatory cells, and the substances these cells secrete, along with non-cellular components in the extracellular matrix (ECM). First, the TME mainly plays a role in inhibiting tumor growth and protecting normal cell survival. As tumors progress, the TME gradually becomes a place to promote tumor cell progression. Immune cells in the TME have attracted much attention as targets for immunotherapy. Immune checkpoint inhibitor (ICI) therapy has the potential to regulate the TME, suppressing factors that facilitate tumor advancement, reactivating immune cells, managing tumor growth, and extending the survival of patients with advanced cancer. This review presents an outline of current studies on the distinct cellular elements within the OC TME, detailing their main functions and possible signaling pathways. Additionally, we examine immunotherapy rechallenge in OC, with a specific emphasis on the biological reasons behind resistance to ICIs.

show abstract

Section: The Potential Of Antitumor Therapy On the Immune Microenviro...mentioning

confidence: 99%